Insulet/$PODD

1D1W1MYTD1Y5YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Ticker
$PODD
Sector
Health
Primary listing
NASDAQ
Employees
5,400
Headquarters
Acton, United States
Website
www.insulet.com

Insulet Metrics

BasicAdvanced
$9.7B
26.29
$5.30
1.09
-

What the Analysts think about Insulet

Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Analyst projections of the future price of Insulet stock.

Bulls say / Bears say

Insulet raised its full-year 2026 revenue growth guidance to 21–23% in constant currency, up from the prior 20–22% range, after exceeding expectations in Q1, underlining strong demand for its Omnipod insulin pump systems. (Reuters)
First-quarter 2026 revenue climbed 34% year-on-year to $761.7 million, surpassing the $728.4 million consensus estimate and reflecting robust Omnipod adoption and operational leverage across the business. (Reuters)
The June 3, 2026 U.S. rollout of an enhanced Omnipod 5 algorithm delivers smarter automation, expanded personalization with a 100 mg/dL target option, and compatibility with Abbott’s FreeStyle Libre 3 Plus, likely boosting user retention and differentiation. (Reuters)
Insulet’s voluntary medical device corrections in March and May 2026 are expected to cost up to $40 million and $50 million respectively, reflecting manufacturing quality issues that may pressure profitability and customer confidence. (SEC, Reuters)
Analysts warn that next-generation tubeless pumps from Tandem, Beta Bionics and Medtronic, slated to reach the market by late 2026, could erode Insulet’s market share and pricing power amid intensifying competitive pressure. (Reuters)
After reporting $801.7 million in Q2 2026 revenue, Insulet cut its full-year 2026 revenue growth forecast to 20–22% from 21–23% on slower U.S. Omnipod sales, sending shares down more than 12%. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.

Insulet Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Insulet Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Insulet News

AllArticlesVideos

PODD DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026

Business Wire2 weeks ago

PODD DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important August 31 Deadline in Securities Class Action - PODD

Newsfile Corp2 weeks ago

PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law

Business Wire2 weeks ago

Funds containing Insulet

AllUSDEURGBP
Funds
Fund name
Fund size
$PODD weighting
iShares Healthcare Innovation$HEAL
$1.4B1.00%
iShares Healthcare Innovation€2B78
€1.2B1.00%
iShares Healthcare Innovation£DRDR
£1B1.00%
iShares S&P 500 Equal Weight€O4J0
€4.3B0.17%
iShares S&P 500 Equal Weight£EWSP
£3.7B0.17%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.